BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

597 related articles for article (PubMed ID: 33236799)

  • 1. Suitability of two rapid lateral flow immunochromatographic assays for predicting SARS-CoV-2 neutralizing activity of sera.
    Valdivia A; Torres I; Latorre V; Francés-Gómez C; Ferrer J; Forqué L; Costa R; de la Asunción CS; Huntley D; Gozalbo-Rovira R; Buesa J; Giménez E; Rodríguez-Díaz J; Geller R; Navarro D
    J Med Virol; 2021 Apr; 93(4):2301-2306. PubMed ID: 33236799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inference of SARS-CoV-2 spike-binding neutralizing antibody titers in sera from hospitalized COVID-19 patients by using commercial enzyme and chemiluminescent immunoassays.
    Valdivia A; Torres I; Latorre V; Francés-Gómez C; Albert E; Gozalbo-Rovira R; Alcaraz MJ; Buesa J; Rodríguez-Díaz J; Geller R; Navarro D
    Eur J Clin Microbiol Infect Dis; 2021 Mar; 40(3):485-494. PubMed ID: 33404891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical diagnostic performance evaluation of five immunoassays for antibodies to SARS-CoV-2 diagnosis in a real-life routine care setting.
    Akyala AI; Awayimbo JR; Ogo AC; Chima NJ; Billyrose OMA; Engom AOG
    Pan Afr Med J; 2021; 39():3. PubMed ID: 34178231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating SARS-CoV-2 spike and nucleocapsid proteins as targets for antibody detection in severe and mild COVID-19 cases using a Luminex bead-based assay.
    Mariën J; Ceulemans A; Michiels J; Heyndrickx L; Kerkhof K; Foque N; Widdowson MA; Mortgat L; Duysburgh E; Desombere I; Jansens H; Van Esbroeck M; Ariën KK
    J Virol Methods; 2021 Feb; 288():114025. PubMed ID: 33227340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.
    Tarkowski M; de Jager W; Schiuma M; Covizzi A; Lai A; Gabrieli A; Corbellino M; Bergna A; Ventura CD; Galli M; Riva A; Antinori S
    Front Immunol; 2021; 12():793191. PubMed ID: 34975897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development, performance evaluation, and clinical application of a Rapid SARS-CoV-2 IgM and IgG Test Kit based on automated fluorescence immunoassay.
    Kang K; Huang L; Ouyang C; Du J; Yang B; Chi Y; He S; Ying L; Chen G; Wang J
    J Med Virol; 2021 May; 93(5):2838-2847. PubMed ID: 33231312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Three Quantitative Anti-SARS-CoV-2 Antibody Immunoassays.
    Chapuy-Regaud S; Miédougé M; Abravanel F; Da Silva I; Porcheron M; Fillaux J; Diméglio C; Izopet J
    Microbiol Spectr; 2021 Dec; 9(3):e0137621. PubMed ID: 34937195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Highly Sensitive and Specific SARS-CoV-2 Spike- and Nucleoprotein-Based Fluorescent Multiplex Immunoassay (FMIA) to Measure IgG, IgA, and IgM Class Antibodies.
    Solastie A; Virta C; Haveri A; Ekström N; Kantele A; Miettinen S; Lempainen J; Jalkanen P; Kakkola L; Dub T; Julkunen I; Melin M
    Microbiol Spectr; 2021 Dec; 9(3):e0113121. PubMed ID: 34787485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A highly specific and sensitive serological assay detects SARS-CoV-2 antibody levels in COVID-19 patients that correlate with neutralization.
    Peterhoff D; Glück V; Vogel M; Schuster P; Schütz A; Neubert P; Albert V; Frisch S; Kiessling M; Pervan P; Werner M; Ritter N; Babl L; Deichner M; Hanses F; Lubnow M; Müller T; Lunz D; Hitzenbichler F; Audebert F; Hähnel V; Offner R; Müller M; Schmid S; Burkhardt R; Glück T; Koller M; Niller HH; Graf B; Salzberger B; Wenzel JJ; Jantsch J; Gessner A; Schmidt B; Wagner R
    Infection; 2021 Feb; 49(1):75-82. PubMed ID: 32827125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A homogeneous split-luciferase assay for rapid and sensitive detection of anti-SARS CoV-2 antibodies.
    Yao Z; Drecun L; Aboualizadeh F; Kim SJ; Li Z; Wood H; Valcourt EJ; Manguiat K; Plenderleith S; Yip L; Li X; Zhong Z; Yue FY; Closas T; Snider J; Tomic J; Drews SJ; Drebot MA; McGeer A; Ostrowski M; Mubareka S; Rini JM; Owen S; Stagljar I
    Nat Commun; 2021 Mar; 12(1):1806. PubMed ID: 33753733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative SARS-CoV-2 Serology in Children With Multisystem Inflammatory Syndrome (MIS-C).
    Rostad CA; Chahroudi A; Mantus G; Lapp SA; Teherani M; Macoy L; Tarquinio KM; Basu RK; Kao C; Linam WM; Zimmerman MG; Shi PY; Menachery VD; Oster ME; Edupuganti S; Anderson EJ; Suthar MS; Wrammert J; Jaggi P
    Pediatrics; 2020 Dec; 146(6):. PubMed ID: 32879033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Assessment of Serological Assays for SARS-CoV-2 as Surrogates for Authentic Virus Neutralization.
    Wohlgemuth N; Whitt K; Cherry S; Kirkpatrick Roubidoux E; Lin CY; Allison KJ; Gowen A; Freiden P; Allen EK; ; Gaur AH; Estepp JH; Tang L; Mori T; Hijano DR; Hakim H; McGargill MA; Krammer F; Whitt MA; Wolf J; Thomas PG; Schultz-Cherry S
    Microbiol Spectr; 2021 Oct; 9(2):e0105921. PubMed ID: 34704832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of a multiplexed coronavirus antigen array for detection of SARS-CoV-2 specific IgG in COVID-19 convalescent plasma.
    Huey L; Andersen G; Merkel PA; Morrison TE; McCarthy M; DomBourian MG; Annen K; Dawson ED; Rowlen KL; Knight V
    J Immunol Methods; 2021 Oct; 497():113104. PubMed ID: 34303688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Performance evaluation of three automated quantitative immunoassays and their correlation with a surrogate virus neutralization test in coronavirus disease 19 patients and pre-pandemic controls.
    Jung K; Shin S; Nam M; Hong YJ; Roh EY; Park KU; Song EY
    J Clin Lab Anal; 2021 Sep; 35(9):e23921. PubMed ID: 34369009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of SARS-CoV-2 neutralizing antibodies using a vesicular stomatitis virus possessing SARS-CoV-2 spike protein.
    Tani H; Kimura M; Tan L; Yoshida Y; Ozawa T; Kishi H; Fukushi S; Saijo M; Sano K; Suzuki T; Kawasuji H; Ueno A; Miyajima Y; Fukui Y; Sakamaki I; Yamamoto Y; Morinaga Y
    Virol J; 2021 Jan; 18(1):16. PubMed ID: 33435994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SARS-CoV-2 Serologic Assays in Control and Unknown Populations Demonstrate the Necessity of Virus Neutralization Testing.
    Rathe JA; Hemann EA; Eggenberger J; Li Z; Knoll ML; Stokes C; Hsiang TY; Netland J; Takehara KK; Pepper M; Gale M
    J Infect Dis; 2021 Apr; 223(7):1120-1131. PubMed ID: 33367830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Rapid, Multiplex Dual Reporter IgG and IgM SARS-CoV-2 Neutralization Assay for a Multiplexed Bead-Based Flow Analysis System.
    Angeloni S; Cameron A; Pecora ND; Dunbar S
    J Vis Exp; 2021 Apr; (170):. PubMed ID: 33900295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Performance of anti-SARS-CoV-2 antibody testing in asymptomatic or mild COVID-19 patients: A retrospective study in outbreak on a cruise ship.
    Kaku N; Nishimura F; Shigeishi Y; Tachiki R; Sakai H; Sasaki D; Ota K; Sakamoto K; Kosai K; Hasegawa H; Izumikawa K; Ariyoshi K; Mukae H; Yasuda J; Morita K; Kohno S; Yanagihara K
    PLoS One; 2021; 16(9):e0257452. PubMed ID: 34582459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Robust validation and performance comparison of immunogenicity assays assessing IgG and neutralizing antibodies to SARS-CoV-2.
    Bonhomme ME; Bonhomme CJ; Strelow L; Chaudhari A; Howlett A; Breidenbach C; Hester J; Hammond C; Fuzy M; Harvey L; Swanner V; Ellis J; Greway RR; Pisciella VA; Green T; Kierstead L
    PLoS One; 2022; 17(2):e0262922. PubMed ID: 35130298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical validation of a second generation anti-SARS-CoV-2 IgG and IgM automated chemiluminescent immunoassay.
    Pieri M; Nuccetelli M; Nicolai E; Sarubbi S; Grelli S; Bernardini S
    J Med Virol; 2021 Apr; 93(4):2523-2528. PubMed ID: 33463719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.